Sanofi Brings SARS Experience to Hunt for Coronavirus Vaccine
- Drugmaker follows efforts by J&J, GSK to speed up development
- Sanofi to rely on recombinant technology with U.S. authority
This scanning electron microscope image shows coronavirus cultured in the lab.
Source: NIAID-RMLThis article is for subscribers only.
French pharmaceutical company Sanofi jumped into the race to combat the fast-spreading coronavirus, betting that earlier work in pursuit of a SARS vaccine could accelerate its effort.
The drugmaker is teaming up with the U.S. Biomedical Advanced Research and Development Authority, or BARDA, an agency inside the American government that funds R&D efforts for health threats. Sanofi previously worked on a vaccine for severe acute respiratory syndrome, or SARS, the related virus responsible for a 2002-2003 epidemic.